Initiated limited U.S. commercial launch of the Pure-Vu ® EVS Gastro and Gen 4 Colon system, including successful UGI procedures at several leading hospital systems The Company is engaged in the process to seek strategic partnerships aimed at accelerating commercialization of the Pure-Vu System and maximizing stockholder value Recent exercise of certain outstanding warrants provided infusion of $2.7M in gross proceeds to the... Read More

FORT LAUDERDALE, Fla., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. (Nasdaq: MOTS, or “Motus” or “the Company”), a medical technology company focused on improving endoscopic outcomes and experiences, today announced that it has entered into a definitive agreement for the immediate exercise of an outstanding Series B common stock purchase warrant held by an institutional investor to purchase an aggregate of... Read More

FORT LAUDERDALE, Fla., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. (“the “Company”) (NASDAQ: MOTS), a medical technology company focused on improving endoscopic outcomes and experiences, today announced that the United States Patent and Trademark Office (USPTO) has issued the Company a new patent (patent # 11904085) titled, “Colon Cleaning System with Automatic Self-Purging Feature.” “We are pleased to announce... Read More

FORT LAUDERDALE, Fla., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. (“the Company”) (NASDAQ: MOTS), today announced that its special meeting of stockholders held on February 16, 2024 (the “Special Meeting”) was convened and then adjourned, without conducting any business, in order to provide stockholders additional time within which to vote on the proposal described in the Company’s definitive proxy statement... Read More

FORT LAUDERDALE, Fla., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. (Nasdaq: MOTS, or “Motus GI” or “the Company”), a medical technology company focused on improving endoscopic outcomes and experiences, announced today the publication of positive data from a study of the second generation Pure-Vu System in a manuscript titled, “An intraprocedural bowel cleansing system for difficult-to-prepare patients—A... Read More

FORT LAUDERDALE, Fla., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. (Nasdaq: MOTS, or “Motus GI” or “the Company”), a medical technology company focused on improving endoscopic outcomes and experiences, announced today the pricing of a public offering of 3,333,334 shares of common stock (or pre-funded warrants in lieu thereof), Series A common warrants to purchase up to 3,333,334 shares of common stock, and... Read More

First case performed using the new FDA cleared Pure-Vu® EVS Gastro system, and expect to initiate broader market introductions by the end of 2023 Pure-Vu EVS Gastro addresses the Upper GI market, an area of high unmet clinical need, including approximately 400,000 cases of upper GI bleeds per year in the U.S. according to iData Research Inc. The Company continues its exploration process to target strategic and financing... Read More

The upper GI procedure was performed by Dr. Brian Hanson, gastroenterologist and Assistant Professor, Medicine, at the University of Minnesota Pure-Vu EVS Gastro addresses the Upper GI market, an area of high unmet clinical need, including approximately 400,000 cases of upper GI bleeds per year in the U.S. according to iData... Read More

FORT LAUDERDALE, Fla., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company focused on improving endoscopic outcomes and experiences, announced today that it will effect a 1-for-15 reverse stock split of its outstanding common stock. The Company’s common stock will begin trading on a split-adjusted basis at the opening of the market on Thursday,... Read More

Clearance opens up the potential breakthrough opportunity in the Upper GI market, an area of high unmet clinical need Technological advancements featured in new generation of the Pure-Vu platform, enhance the performance of the system, improve the ease of use and minimizes the need for onsite support to new accounts Expect to initiate market introduction of the new Pure-Vu EVS platform by year-end for both the Upper GI and... Read More

A special 510(k), according to FDA guidance, is usually reviewed within 30 days of receipt Pure-Vu Gen 4 platform opens up the Upper GI market, reduces the cost-of-goods by approximately 50% and minimizes the need for onsite support to new accounts FORT LAUDERDALE, Fla., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. , (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company focused on improving... Read More

Amended agreement eliminates approximately $1.0M in contingent royalty obligations from balance sheet Canceled royalty rights in exchange for common stock expected to improve Company’s stockholder equity, and simplify ongoing exploration of strategic and financing alternatives to maximize stockholder value FORT LAUDERDALE, Fla., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. , (NASDAQ: MOTS) (“Motus GI” or the... Read More

FORT LAUDERDALE, Fla., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. , (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company focused on improving endoscopic outcomes and experiences, announced the appointment of Scott Durbin to the Company’s Board of Directors (the “Board”). Mr. Durbin has more than 25 years of executive leadership, finance and clinical development experience, including the... Read More

FORT LAUDERDALE, Fla., Aug. 24, 2023 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. , (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company focused on improving endoscopic outcomes and experiences, announced today that Mark Pomeranz, President and Chief Executive Officer, will present at the H.C. Wainwright 25 th Annual Global Investment Conference. H.C. Wainwright 25 th Annual Global Investment Conference... Read More

On track to submit planned special 510(k) for Pure-Vu Gen 4 Gastro and Colon to the FDA in Q4 2023; Received system wide approval in the Banner Medical Hospital Network and installed the first system at the Banner Dessert Medical Center in Mesa, Ariz. The Company continues its exploration process to target strategic and financing alternatives aimed at accelerating commercialization of the Pure-Vu System and maximizing... Read More

FORT LAUDERDALE, Fla., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. , (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company focused on improving endoscopic outcomes and experiences, today announced that it has received approval from the Israeli Ministry of Health, Medical Device Division (known as "AMAR") to initiate commercial sales of the Pure-Vu ® EVS System in Israel. “We are pleased to... Read More

Implementation of the Pure-Vu system designed to improve efficiencies and outcomes of GI endoscopy procedures Initial agreement expected to provide an easier sales process to the other more than 30 medical centers within the Banner Medical network FORT LAUDERDALE, Fla., July 20, 2023 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. , (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company focused on improving... Read More

Pure-Vu system featured in live case during an underwater large polyp resection in the colon Over 1,000 physicians registered for IECED Live Endoscopy Course from across Latin America Pure-Vu Gen 4 Gastro and Colon on track for FDA submission in Q4 2023 FORT LAUDERDALE, Fla., June 14, 2023 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company focused on... Read More

Company completes corporate reorganization focused on reducing operating costs while supporting key value creation drivers, including seeking key FDA approvals and pursuit of strategic partnerships to accelerate commercialization FORT LAUDERDALE, Fla., June 05, 2023 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company focused on improving endoscopic outcomes... Read More

FORT LAUDERDALE, Fla., May 18, 2023 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. , (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company focused on improving endoscopic outcomes and experiences, today announced that it has entered into definitive agreements for the issuance and sale of an aggregate of 4,142,012 shares of its common stock (or common stock equivalent in lieu thereof) and warrants to... Read More

Pure-Vu Gastro achieves high usability scores in supporting upper endoscopy procedures with first time users - On track to submit a 510(k) to the U.S. FDA for the Pure-Vu Gen 4 Gastro device in Q4 2023 to support the 400,000 upper GI bleeds and other procedures with impaired visualization in the U.S. Pure-Vu Gen 4 Gastro to be used during the 9 th IECED Live Endoscopy Course 2023 through the Pentax Learning Center in June... Read More

FORT LAUDERDALE, Fla., May 11, 2023 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. , (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, today announced that an abstract of new clinical data from the University of Minnesota and... Read More

■ Oral presentation at the Digestive Disease Week 2023 featured positive clinical data showing a reduction of 33% in incomplete bowel prep (IBP)in just six months after implementation of the Pure-Vu® system at the Minneapolis VA Medical Center ■ The Company is advancing its development of Pure-Vu EVS Gastro, designed for Upper GI bleeding procedures - an area of high unmet patient need - and expects submission of the 510(k)... Read More

New company name chosen to represent focus on ‘averting’ serious cardiac complications with state-of-the-art Guardian™ monitoring and alerting system President and CEO Tim Moran and Chief Financial Officer Philip Tom to join Executive Chairman Ross Haghighat in leadership roles EATONTOWN, N.J., April 27, 2023 (GLOBE NEWSWIRE) -- Angel Medical Systems Inc. (dba AngelMed), a company focused on improving long-term management of... Read More

Tim Moran transitions from Chief Executive Officer to Chairman of the Board and Mark Pomeranz appointed Chief Executive Officer to lead next phase of Company Restructuring plan reduces operating expenses by an additional ~25%, extending cash runway to support FDA submission of Pure-Vu Upper GI and fourth generation Lower GI product before the end of 2023 FORT LAUDERDALE, Fla. , April 13, 2023 (GLOBE NEWSWIRE) -- Motus GI... Read More

The Company continues its exploration process to target strategic and financing alternatives aimed at accelerating commercialization of the Pure-Vu System and maximizing stockholder value The Company is actively supporting its existing installed customer base and pipeline opportunities in contracted health systems The Company is advancing its development of Pure-Vu EVS Gastro, designed for Upper GI bleeding procedures, and... Read More

Lake Street Capital Markets LLC engaged to act as an advisor to the Company Board of Directors approved restructuring program with the objective of preserving capital to align with strategic process timeline Management plans to continue providing sales and support for existing Pure-Vu EVS customers and pipeline opportunities in contracted health systems Company to move forward with regulatory process and commercial readiness... Read More

Pre-clinical tests show enhanced functionality of Pure-Vu EVS that can enable physicians to overcome common visualization challenges encountered during emergency upper GI bleeding procedures Additional pre-clinical and clinical tests of Pure-Vu EVS System are planned in 1H 2023; development program on track to submit 510(K) application to FDA in 2H 2023 Company intends to evaluate potential strategic distribution and... Read More